{'Year': '2016', 'Month': 'Sep'}
Polymorphisms in SLCO1B1 and UGT1A1 are associated with sorafenib-induced toxicity.
Sorafenib-treated patients display a substantial variation in the incidence of toxicity. We aimed to investigate the association of genetic polymorphisms with observed toxicity on sorafenib.